Figure 1 (Rybrevant 01)
Rybrevant Faspro Injection
Product Images NDC 57894-522
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rybrevant Faspro (NDC 57894-522). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Janssen Biotech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Rybrevant 02)
This is a chart presenting the comparison between Intravenous amivantamab + lazertinib and Osimertinib treatments over a period of months. The chart displays the effectiveness of each treatment and the number of participants at risk during the study.*
Figure 3 (Rybrevant 03)
Figure 4 (Rybrevant 04)
Principal Display Panel (10 mL Vial Carton)
Description: This is a pharmaceutical label for a medication called Rybrevant Faspro™. It is an injectable solution containing amivantamab and hyaluronidase-lpuj used for subcutaneous injection by a healthcare provider. The dosage is 1,600 mg and 20,000 units/10 mL. The injection should not be frozen or shaken and should be administered over approximately 5 minutes. The single-dose vial does not contain a preservative. The label provides specific dosing instructions and details about the manufacturer.*
Principal Display Panel (14 mL Vial Carton)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
